EGFR and neoplasm: Orlistat anti‐tumor activity in vivo was further validated in transgenic mouse model expressing the clinically relevant EGFR T790M/L858R mutation, in which at termination of treatment, drug‐exposed animals presented with approximately 30% decrease in tumor mass (assessed by MRI) as compared to vehicle‐treated transgenic mice.